This article is more than 5 years old. Information may no longer be current.
HF malignancy similar to certain cancers
Click Here to Manage Email Alerts
In patients with HF, survival outcomes were worse than for those with certain kinds of cancer but better than for those with other kinds, according to findings.
“Our study shows that despite advances in the treatment of [HF] with newer drugs and devices, mortality rates for patients with [HF] remain significant and a major public health problem,” Mamas A. Mamas, DPhil, MRCP, professor of cardiology in the Keele Cardiovascular Research Group at the University of Keele, Stoke-on-Trent, United Kingdom, said in a press release. “[HF] remains as malignant as many of the common cancers.”
Mamas and colleagues analyzed 56,658 participants from a Scottish database with median follow-up of 2.04 years, for a total of 147,938 person-years of follow-up. They performed sex-specific survival modeling to compare 5-year survival rates in those with HF with 5-year survival rates in those with various forms of cancer.
The 5-year survival rate in those with HF was 55.8%.
Among men, those with HF had worse 5-year survival outcomes than those with prostate cancer (68.3%; HR = 0.61; 95% CI, 0.57-0.65) and those with bladder cancer (57.3%; HR = 0.88; 95% CI, 0.81-0.96), but better 5-year survival outcomes than those with lung cancer (8.4%; HR = 3.86; 95% CI, 3.65-4.07) and colorectal cancer (48.9%; HR = 1.23; 95% CI, 1.16-1.31), according to the researchers.
For women, those with HF had worse 5-year survival outcomes than those with breast cancer (77.7%; HR = 0.55; 95% CI, 0.51-0.59) but better 5-year survival outcomes than those with colorectal cancer (51.5%; HR = 1.21; 95% CI, 1.13-1.29), lung cancer (10.4%; HR = 3.82; 95% CI, 3.6-4.05) and ovarian cancer (38.2%; HR = 1.98; 95% CI, 1.8-2.17), Mamas and colleagues wrote.
“Our results highlight the substantial multimorbidity associated with HF that will represent a significant challenge to the delivery of health care in the future, particularly as the burden of HF continues to grow,” the researchers wrote. “Targeted management of the comorbidities common in HF may be associated with better survival and quality of life in this population.” – by Erik Swain
Disclosures: The researchers report no relevant financial disclosures.
Click Here to Manage Email Alerts